We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-9.09%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.4B
AUM Growth
-$3.15B
Cap. Flow
+$225M
Cap. Flow %
1.29%
Top 10 Hldgs %
85.01%
Holding
121
New
2
Increased
15
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$184M
2
KOD icon
Kodiak Sciences
KOD
+$48.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.2M
4
TSVT
2seventy bio
TSVT
+$20.9M
5
REPL icon
Replimune Group
REPL
+$19.2M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$20.1M
2
LEGN icon
Legend Biotech
LEGN
+$19M
3
OPT
Opthea Limited American Depositary Shares
OPT
+$3.19M
4
ALBO
Albireo Pharma Inc
ALBO
+$2.43M
5
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$1.55M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CABA icon
101
Cabaletta Bio
CABA
$429M
$1.34M 0.01%
662,063
– –
NEXI
102
DELISTED
NexImmune, Inc. Common Stock
NEXI
$1.24M 0.01%
11,765
– –
EPZM
103
DELISTED
Epizyme, Inc
EPZM
$1.15M 0.01%
+1,000,000
New +$1.63M
TARA icon
104
Protara Therapeutics
TARA
$213M
$1.02M 0.01%
199,671
– –
GTH
105
DELISTED
Genetron Holdings Limited ADS
GTH
$997K 0.01%
151,769
– –
CYPH
106
Cypherpunk Technologies Inc
CYPH
$63.1M
$979K 0.01%
55,971
– –
VINC
107
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$966K 0.01%
12,069
– –
SERA icon
108
Sera Prognostics
SERA
$80.7M
$764K ﹤0.01%
201,562
– –
OYST
109
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$715K ﹤0.01%
61,424
– –
FHTX icon
110
Foghorn Therapeutics
FHTX
$278M
$686K ﹤0.01%
45,027
– –
BLCM
111
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$538K ﹤0.01%
249,123
– –
INZY
112
DELISTED
Inozyme Pharma
INZY
$438K ﹤0.01%
106,999
– –
PASG icon
113
Passage Bio
PASG
$14.2M
$363K ﹤0.01%
5,858
– –
LOGC
114
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$307K ﹤0.01%
451,478
– –
SRZNW icon
115
Surrozen Inc Warrant
SRZNW
$36.6K
$208K ﹤0.01%
833,333
– –
GMDA
116
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-610,626
Closed -$1.55M
ALBO
117
DELISTED
Albireo Pharma Inc
ALBO
– –
-104,521
Closed -$2.43M
EVFM
118
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
– –
-179,807
Closed -$1.01M
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Baker Bros. Advisors held 121 positions worth $17.4B, down 15% from $20.6B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Trading was light in Q1 2022: portfolio turnover was 4.1%. Baker Bros. Advisors opened 2 new positions and exited 3, leaving the 121-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2022 buy was Vera Therapeutics: 333,333 shares worth $7.83M.
  • Baker Bros. Advisors added most to Incyte in Q1 2022, an estimated $184M increase.
  • Baker Bros. Advisors's biggest Q1 2022 reduction was ChemoCentryx, Inc., cutting an estimated $20.1M.
  • Baker Bros. Advisors fully exited Albireo Pharma Inc in Q1 2022, selling an estimated $2.43M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $17.4B portfolio in Q1 2022.
  • Baker Bros. Advisors opened 2 new positions and closed 3 in Q1 2022.
  • Baker Bros. Advisors's portfolio value fell 15% quarter-over-quarter to $17.4B.

Based on Baker Bros. Advisors's 13F filing for Q1 2022, filed 16 May 2022.